Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy

Jarrett J. Failing, Olivia A. Dudek, Julian A. Marin Acevedo, Razvan M. Chirila, Haidong M Dong, Svetomir Nenad Markovic, Roxana S Dronca

Research output: Contribution to journalReview article

Abstract

Hyperprogression and pseudoprogression are two atypical responses to immune checkpoint inhibitor therapy that affect therapeutic decisions and prognosis. Identification of predictive biomarkers for atypical responses either before or during treatment remains a huge unmet need in cancer immunotherapy. Many studies have looked at potential biomarkers, including clinical factors and laboratory findings (e.g., peripheral blood counts, circulating tumor DNA, cytokine levels). The results of these studies have been inconsistent, possibly due to small sample sizes, different tumor types and heterogeneity of the definition of these atypical responses.

Original languageEnglish (US)
Pages (from-to)2645-2656
Number of pages12
JournalFuture Oncology
Volume15
Issue number22
DOIs
StatePublished - Aug 1 2019

Fingerprint

Biomarkers
Neoplasms
Sample Size
Immunotherapy
Therapeutics
Cytokines
DNA

Keywords

  • atypical response
  • biomarker
  • hyperprogression
  • immune checkpoint inhibitor
  • immunotherapy
  • pseudoprogression

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy. / Failing, Jarrett J.; Dudek, Olivia A.; Marin Acevedo, Julian A.; Chirila, Razvan M.; Dong, Haidong M; Markovic, Svetomir Nenad; Dronca, Roxana S.

In: Future Oncology, Vol. 15, No. 22, 01.08.2019, p. 2645-2656.

Research output: Contribution to journalReview article

Failing, Jarrett J. ; Dudek, Olivia A. ; Marin Acevedo, Julian A. ; Chirila, Razvan M. ; Dong, Haidong M ; Markovic, Svetomir Nenad ; Dronca, Roxana S. / Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy. In: Future Oncology. 2019 ; Vol. 15, No. 22. pp. 2645-2656.
@article{4e853918032a487dad491f9675f19dc6,
title = "Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy",
abstract = "Hyperprogression and pseudoprogression are two atypical responses to immune checkpoint inhibitor therapy that affect therapeutic decisions and prognosis. Identification of predictive biomarkers for atypical responses either before or during treatment remains a huge unmet need in cancer immunotherapy. Many studies have looked at potential biomarkers, including clinical factors and laboratory findings (e.g., peripheral blood counts, circulating tumor DNA, cytokine levels). The results of these studies have been inconsistent, possibly due to small sample sizes, different tumor types and heterogeneity of the definition of these atypical responses.",
keywords = "atypical response, biomarker, hyperprogression, immune checkpoint inhibitor, immunotherapy, pseudoprogression",
author = "Failing, {Jarrett J.} and Dudek, {Olivia A.} and {Marin Acevedo}, {Julian A.} and Chirila, {Razvan M.} and Dong, {Haidong M} and Markovic, {Svetomir Nenad} and Dronca, {Roxana S}",
year = "2019",
month = "8",
day = "1",
doi = "10.2217/fon-2019-0183",
language = "English (US)",
volume = "15",
pages = "2645--2656",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "22",

}

TY - JOUR

T1 - Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy

AU - Failing, Jarrett J.

AU - Dudek, Olivia A.

AU - Marin Acevedo, Julian A.

AU - Chirila, Razvan M.

AU - Dong, Haidong M

AU - Markovic, Svetomir Nenad

AU - Dronca, Roxana S

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Hyperprogression and pseudoprogression are two atypical responses to immune checkpoint inhibitor therapy that affect therapeutic decisions and prognosis. Identification of predictive biomarkers for atypical responses either before or during treatment remains a huge unmet need in cancer immunotherapy. Many studies have looked at potential biomarkers, including clinical factors and laboratory findings (e.g., peripheral blood counts, circulating tumor DNA, cytokine levels). The results of these studies have been inconsistent, possibly due to small sample sizes, different tumor types and heterogeneity of the definition of these atypical responses.

AB - Hyperprogression and pseudoprogression are two atypical responses to immune checkpoint inhibitor therapy that affect therapeutic decisions and prognosis. Identification of predictive biomarkers for atypical responses either before or during treatment remains a huge unmet need in cancer immunotherapy. Many studies have looked at potential biomarkers, including clinical factors and laboratory findings (e.g., peripheral blood counts, circulating tumor DNA, cytokine levels). The results of these studies have been inconsistent, possibly due to small sample sizes, different tumor types and heterogeneity of the definition of these atypical responses.

KW - atypical response

KW - biomarker

KW - hyperprogression

KW - immune checkpoint inhibitor

KW - immunotherapy

KW - pseudoprogression

UR - http://www.scopus.com/inward/record.url?scp=85070791797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070791797&partnerID=8YFLogxK

U2 - 10.2217/fon-2019-0183

DO - 10.2217/fon-2019-0183

M3 - Review article

VL - 15

SP - 2645

EP - 2656

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 22

ER -